Open Access
Subscription Access
T-Cells and Cancer Immunotherapy (Immuno-Oncology):The 2018 Nobel Prize in Physiology or Medicine
The 2018 Nobel Prize in Physiology or Medicine has been awarded to two scientists, James P. Allison and Tasuku Honjo for discovery of checkpoint molecules CTLA-4 and PD-1, which inhibit the T-cells of the im-mune system from attacking the cancerous tumours. They also discovered antibodies, which could be used for inhibiting the activity of these checkpoint molecules, thus relieving the T-cells from inhibitory activity of checkpoints, to be able to attack cancerous tumours. Such antibodies have already been converted into a number of immunotherapeutic drugs, which have been approved and are already being used for treatment of a variety of cancers.
User
Font Size
Information
- The Nobel Prize in Physiology or Medi-cine 2018. 1 October 2018, NobelPrize. org. Nobel Media AB 2018; https:// www.nobelprize.org/prizes/medicine/2018/summary/
- Harding, F. A. et al., Nature, 1992, 356, 607–609.
- Harding, F. A. and Allison, J. P., J. Exp. Med., 1993, 177, 1791–1796.
- Tivol, E. A. et al., Immunity, 1995, 3, 541–547.
- Thompson, C. B. and Allison, J. P., Im-munity, 1997, 7, 445–450.
- Waterhouse, P. et al., Science, 1995, 270, 985–988.
- Leach, D. R., Krummel, M. F. and Alli-son, J. P., Science, 1996, 271, 1734–1736.
- Hurwitz, A. A. et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 10067–10071.
- Phan, G. Q. and Rosenberg, S. A., Proc. Natl. Acad. Sci. USA, 2003, 100, 8372–8377.
- Lipson, E. J. and Drake, C. G., Clin. Cancer Res., 2011, 17, 6958–6962.
- Honjo, T. and Kataoka, T., Proc. Natl. Acad. Sci. USA, 1978, 75, 2140–2144.
- Ishida, Y., EMBO J., 1992, 11, 3887–3895.
- Agata, Y. et al., Int. Immunol., 1996, 8, 765–772.
- Vibhakar, R. G., Exp. Cell Res., 1997, 232, 25–28.
- Shinohara, T. M., Genomics, 1994, 23, 704–706.
- Agata, Y. A., Int. Immunol., 1996, 8, 765–772.
- Nishimura, H. et al., Int. Immunol., 1998, 10, 563–1572.
- Nishimura, H. et al., Immunity, 1999, 11, 141–151.
- Iwai1, Y., Terawaki, S. and Honjo, T., Int. Immunol., 2004, 17, 133–144.
- Freeman, G. J., J. Exp. Med., 2000, 192, 1027–1034.
- Berger, R. et al., Clin. Cancer Res., 2008, 14, 3044–3051.
- https://www.onclive.com/web-exclusives/fda-approves-pembrolizumab-for-advanced-melanoma
- Walker, L. S. K., Sci. Immunol., 2017, eaan3864.
- Bally, A. et al., J. Immunol., 2016, 196, 2431–2437.
- Alsaab, H. O. et al., Fron. Pharmacol., 2017, 8, 561.
- Barbee, M. S., Ann. Pharmacother., 2015, 49, 907–937.
- Hirschler, B., Health News, 7 December 2017.
- Schmidt, C., Nature, 2017, 552(7685), S67–S69.
- Naidoo, J., Ann. Oncol., 2015, 26, 2375–2391.
- Ventola, C. L., Pharmacy Therapetics, 2017, 42, 514–521.
- Ayers, M. et al., J. Clin. Invest., 2017, 127, 2930–2940.
- Cristescu, R., Science, 2018, 362 (pub-lished on-line on 12 October 2018; doi:10.1126/science.aar3593
Abstract Views: 376
PDF Views: 137